Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
:YMAB
YMAB Analyst Ratings
Hold
0 Buy
10 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
YMAB Stock 12 Month Forecast
Average Price Target
$7.98
▼(-6.34% Downside)
| Highest Price Target$8.60 | Average Price Target$7.98 | Lowest Price Target$3.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$11→$8.6
Hold
0.94%
Upside
Downgraded
08/06/25
Valuation and Risks. We originally assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which utilized a 95% and 100% probability of approval for naxitamab in front-line neuroblastoma (1L NB) and r/r NB, respectively, and a 10% probability of approval for the GD2-SADA in 3L melanoma, 2/3L SCLC, and osteosarcoma. We employed a 10% discount rate and 27.5% effective tax rate. These generated a market value of the firm of $481M, or a price objective of $11 per share, assuming ~45.6M shares outstanding.
Wedbush
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Clear Street
$17→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Truist Financial
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Morgan Stanley
$7→$8.6
Hold
0.94%
Upside
Upgraded
08/05/25
Brookline Capital Markets
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
JonesTrading
―
Hold
―
Downgraded
08/05/25
Canaccord Genuity
$26→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Cantor Fitzgerald
$19→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Oppenheimer
―
Hold
―
Downgraded
08/05/25
Bank of America Securities
$3
Sell
-64.79%
Downside
Reiterated
07/22/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$11→$8.6
Hold
0.94%
Upside
Downgraded
08/06/25
Valuation and Risks. We originally assessed Y-mAbs using a discounted cash flow (DCF)-based methodology, which utilized a 95% and 100% probability of approval for naxitamab in front-line neuroblastoma (1L NB) and r/r NB, respectively, and a 10% probability of approval for the GD2-SADA in 3L melanoma, 2/3L SCLC, and osteosarcoma. We employed a 10% discount rate and 27.5% effective tax rate. These generated a market value of the firm of $481M, or a price objective of $11 per share, assuming ~45.6M shares outstanding.
Wedbush
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Clear Street
$17→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Truist Financial
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Morgan Stanley
$7→$8.6
Hold
0.94%
Upside
Upgraded
08/05/25
Brookline Capital Markets
$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
JonesTrading
―
Hold
―
Downgraded
08/05/25
Canaccord Genuity
$26→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Cantor Fitzgerald
$19→$8.6
Hold
0.94%
Upside
Downgraded
08/05/25
Oppenheimer
―
Hold
―
Downgraded
08/05/25
Bank of America Securities
$3
Sell
-64.79%
Downside
Reiterated
07/22/25
Best Analysts Covering Y-Mabs Therapeutics
1 Month
xxx
Success Rate
8/19 ratings generated profit
Average Return
-3.26%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.11% of your transactions generating a profit, with an average return of -3.26% per trade.
3 Months
xxx
Success Rate
8/19 ratings generated profit
Average Return
+3.19%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of +3.19% per trade.
1 Year
Success Rate
1/6 ratings generated profit
Average Return
-69.55%
reiterated a sell rating 18 days ago
Copying Alec Stranahan's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of -69.55% per trade.
2 Years
xxx
Success Rate
4/19 ratings generated profit
Average Return
-22.27%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 21.05% of your transactions generating a profit, with an average return of -22.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
YMAB Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
10
20
13
12
2
Buy
1
1
1
1
0
Hold
5
4
1
0
9
Sell
3
7
6
5
1
Strong Sell
0
0
0
0
0
total
19
32
21
18
12
Each month's total comprises the sum of three months' worth of ratings.
YMAB Financial Forecast
YMAB Stock Forecast FAQ
What is YMAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Y-Mabs Therapeutics’s 12-month average price target is 7.98.
What is YMAB’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for YMAB, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is YMAB a Buy, Sell or Hold?
Y-Mabs Therapeutics has a consensus rating of Hold which is based on 0 buy ratings, 10 hold ratings and 1 sell ratings.
What is Y-Mabs Therapeutics’s price target?
The average price target for Y-Mabs Therapeutics is 7.98. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $8.60 ,the lowest forecast is $3.00. The average price target represents -6.34% Decrease from the current price of $8.52.
The highest analyst price target is $8.60 ,the lowest forecast is $3.00. The average price target represents -6.34% Decrease from the current price of $8.52.
What do analysts say about Y-Mabs Therapeutics?
Y-Mabs Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of YMAB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.